ImmunityBio, Inc. (IBRX) stock analysis
In our weekly check, ImmunityBio, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 11.
About ImmunityBio, Inc.
ImmunityBio, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IBRX.
What our checks show for IBRX
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from, and equity is negative: on the balance sheet, liabilities exceed assets.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The gross margin fell by 3.3 points, to 96.7%: costs are rising faster than prices.
- Earnings per share grew only 1% a year over the last 3 years.
- The company is losing money: the net margin is -608%.
- Free cash flow is negative (-163% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 101% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 97% from a peak. Would you have held through that?
- The share count grew by 80.8% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Analysts expect earnings per share to shrink about 62.2% a year.
- Recovering from its deepest fall took about 1.7 years.
Strengths
- The net margin rose by 36522 points over 5 years, to -608%.
- Analysts expect revenue to grow about 94.9% a year over the next years.
- Analysts expect the net margin to improve by 622 points from today's -608%.
- Revenue grew 813% a year over the last 3 years.
- Beta 0.13: the stock usually moves less than the market.
- Actively traded: about 12.5 million shares a day.
Similar companies
CAI · BLTE · LGND · CGON · MIRM · ARWR
Questions
What grade does ImmunityBio, Inc. (IBRX) have?
In our weekly check, ImmunityBio, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 11. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of IBRX stock?
This week's biggest flags for ImmunityBio, Inc.: High debt, Weak interest cover, Gross margin falling. In total 13 of 22 checks show a warning or a red flag.
What does ImmunityBio, Inc. do?
ImmunityBio, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IBRX.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis